Abstract Number: 1807 • 2013 ACR/ARHP Annual Meeting
Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?
Background/Purpose: After achieving low disease activity or remission, immunosuppressant therapies might be stopped in lupus patients, but information on whether and how this should be…Abstract Number: 1768 • 2013 ACR/ARHP Annual Meeting
Value Of Arthroscopic Partial Meniscectomy In Treatment Of Symptomatic Patients With Meniscal Tears and Knee Osteoarthritis: Is More Research Warranted?
Background/Purpose: Arthroscopic partial meniscectomy (APM) is often offered to patients with symptomatic meniscal tear (MT). Recent trials in symptomatic patients with MT and knee OA…Abstract Number: 1769 • 2013 ACR/ARHP Annual Meeting
Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden
Background/Purpose: To study direct and indirect costs for patients with Systemic Lupus Erythematosus (SLE) ín five defined cohorts with nationwide spread in Sweden, and to…Abstract Number: 1770 • 2013 ACR/ARHP Annual Meeting
All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System
Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between…Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…Abstract Number: 1773 • 2013 ACR/ARHP Annual Meeting
The Contribution Of Environmental Factors To Familial Risk Of Rheumatoid Arthritis By Serologic Phenotypes Among Women In a Longitudinal Cohort Study
Background/Purpose: Familial risk of RA is composed of shared genetic and environmental factors. Previous studies exploring familial risk of RA have not incorporated environmental factors…Abstract Number: 1774 • 2013 ACR/ARHP Annual Meeting
Sepsis Is The Leading Cause Of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are debilitating inflammatory myopathies with five-year mortality rates estimated to be 33%. However, the leading causes of inpatient…Abstract Number: 1775 • 2013 ACR/ARHP Annual Meeting
Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are associated with interstitial lung disease (ILD), characterized by parenchymal abnormalities on high-resolution computed tomography (HRCT). We determined the…Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…Abstract Number: 1777 • 2013 ACR/ARHP Annual Meeting
Antibodies Against TIF1-Gamma In Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal
Background/Purpose: Antibodies against TIF1-gamma have been detected in patients with cancer associated myositis (CAM) but it is not known whether the antibodies precede the diagnosis…Abstract Number: 1778 • 2013 ACR/ARHP Annual Meeting
Physical Interactions Between Histidyl-tRNA Synthetase and Endogenous/Exogenous Alarmins Enhance Immunogenicity In a Model Of Antigen-Induced Myositis
Objective: To assess the biological interplay between histidyl-tRNA synthetase (HRS) and different endogenous/exogenous ligands capable of generating signals through MyD88-dependent receptor systems in idiopathic inflammatory…Abstract Number: 1779 • 2013 ACR/ARHP Annual Meeting
A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis
Background/Purpose: This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG)…Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…Abstract Number: 1781 • 2013 ACR/ARHP Annual Meeting
Clinical Variation In Children With Mutations In MEFV
Background/Purpose: As a referral clinic for children with periodic fevers, we see a wide variety of clinical presentations. While genetic testing is usually helpful in…